Hisse Senetlerindeki Sıralama
#33514
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Ticaret TME Pharma N.V. (ALTME)
B piyasa değeri ile ALTME fiyatı
Piyasa Değeri TME Pharma N.V.(ALTME)
Piyasa Değeri: $7.16M
August 2026 itibarıyla TME Pharma N.V. şirketinin piyasa değeri $7.16M. Bu, verilerimize göre TME Pharma N.V. şirketini dünyanın en değerli 33514th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
TME Pharma N.V. piyasa değeri geçmişi (2016 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında ALTME
| ALTME’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.452T
|
+76,125,253.52%
|
|
|
|
|
$4.490T
|
+62,694,812.90%
|
|
|
|
|
$4.162T
|
+58,120,294.94%
|
|
|
|
|
$3.676T
|
+51,333,292.80%
|
|
|
|
|
$2.833T
|
+39,558,154.52%
|
